Published June 13, 2023 | Version v1
Patent Open

Car T-cells recognizing cancer-specific IL 13Ra2

  • 1. University of Chicago
  • 2. Baylor College of Medicine

Contributors

Description

Provided are specific binding molecules, or fragments thereof, that bind to an epitope of IL13Rα2, a receptor polypeptide preferentially found on the surface of cancer cells rather than healthy cells. Exemplary specific binding molecules are bispecific binding molecules that comprise a fragment of an IL13Rα2 binding molecule and a peptide providing a second function providing a signaling function of the signaling domain of a T cell signaling protein, a peptide modulator of T cell activation, or an enzymatic component of a labeling system. Also provided are polynucleotides encoding such a specific binding molecule (e.g., bispecific binding molecule), vectors, host cells, pharmaceutical compositions and methods of preventing, treating or ameliorating a symptom associated with a cancer disease such as a solid tumor disease (e.g., glioblastoma multiforme).

Files

US11673934.pdf

Files (14.1 MB)

Name Size Download all
md5:9d5bbdf6c033123bd30c4b4ef78b64e8
14.1 MB Preview Download

Additional details

Identifiers

Patent number
US 11673935 B2
Patent application number
US 201916675861 A
Other
oai:uchicago.tind.io:7766

Dates

Patent filed
2019-11-06

UChicago Information

Division(s)
Biological Sciences Division
Department(s)
Medicine, Neurological Surgery